Drug Profile

Bee venom - Apimeds

Alternative Names: Apitox; Apitoxin; honeybee toxin - Apimeds; purified bee venom - Apimeds

Latest Information Update: 11 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Apimeds
Class Analgesics; Anti-inflammatories; Venoms
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Osteoarthritis
Phase III Multiple sclerosis

Most Recent Events

11 Oct 2021 Bee venom is still in phase III trials for Multiple sclerosis in USA (Intradermal) (Apimeds pipeline, October 2021)
11 Oct 2021 Bee venom is still in phase III trials for Osteoarthritis in USA (Intradermal) (Apimeds pipeline, October 2021)
11 Oct 2021 Apimeds announces intention to submit BLA to US FDA, in 2024 (Apimeds pipeline, October 2021)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com